Page 60 - ARNM-3-1

Advances in Radiotherapy
& Nuclear Medicine The novel index and osteoradionecrosis

Table 4. Results of the univariate and multivariate analyses (ORNJ)
Characteristic All patients (n=220) ORN incidence (n=21) Univariate P-value Multivariate P-value
Age group, n (%)
≤56 years 114 (51.8) 12 (10.5) 0.65 -
>56 years 106 (48.2) 9 (8.5)
Sex, n (%)
Female 69 (31.4) 7 (10.14) 0.81 -
Male 151 (68.6) 14 (9.27)
Smoking history, n (%)
Yes 166 (75.5) 15 (9.03) 0.60 -
No 54 (24.5) 6 (11.11)
Alcohol consumption history, n (%)
Yes 98 (44.5) 10 (10.2) 0.82 -
No 122 (55.5) 11 (9.01)
Continued smoking, n (%)
Yes 47 (21.4) 10 (47.62) 0.002 0.004
No 173 (78.6) 11 (52.38)
Continued alcohol consumption, n (%)
Yes 66 (0.30) 8 (38.1) 0.19 -
No 154 (0.70) 13 (61.9)
T-stage group, n (%)
1 – 2 44 (0.20) 3 (14.3) 0.18 -
3 – 4 176 (0.80) 18 (85.7)
N-stage, n (%)
0 – 1 78 (35.5) 6 (28.6) 0.23 -
2 – 3 142 (64.5) 15 (71.4)
Clinical stage, n (%)
III 79 (35.91) 6 (28.6) 0.27 -
IVA-B 141 (65.09) 15 (71.4)
Concurrent chemotherapy cycles, n (%)
1 55 (0.25) 5 (23.81) 0.88 -
2 – 3 165 (0.75) 16 (76.19)
Adjuvant chemotherapy cycles, n (%)
0 76 (34.55) 7 (33.3) 0.82 -
1 – 2 144 (65.45) 14 (66.7)
Post-C-CRT TE, n (%)
Absent 38 (17.3) 0 (0.0) <0.001 <0.001
Present 182 (82.7) 21 (100.0)
Pre-C-CRT TE group, n (%)
≥4 76 (34.5) 17 (22.4) <0.001 <0.001
<4 127 (65.5) 4 (3.14)
PIV group, n (%)
≥833 66 (30.0) 17 (25.8) <0.001 0.001
<833 154 (70.0) 4 (2.6)
PIV-TE-ORNJ group, n (%)*
Low-risk group 94 (42.7) 1 (1.1) 0.006a 0.009a
Intermediate-risk group 94 (42.7) 6 (6.4) <0.001 b <0.001 b
High-risk group 32 (14.6) 14 (43.75) <0.001 c <0.001 c
MMD group, n (%)
<56.4 Gy 163 (74.1) 4 (19.05) <0.001 0.001
≥56.4 Gy 57 (25.9) 17 (80.95)
Note: *Bonferroni corrected P values for each group (significant Bonferroni corrected P-value for three possible comparisons is 0.0167).
Abbreviations: T: Tumor; N: Node; C-CRT: Concurrent chemoradiotherapy; TE: Tooth extraction; PIV: Pan-immune-inflammation value;
ORNJ: Osteoradionecrosis of jaws; MMD: Mean mandibular dose.

Volume 3 Issue 1 (2025) 52 doi: 10.36922/arnm.5799